In case you missed it: Open Phil would like to fund a science policy think tank


It appears to us that the strongest scientific funders have little interest in policy analysis and advocacy, while the strongest funders of policy analysis and advocacy tend not to take interest in the scientific research issues discussed in this post. We’re interested in the idea of combining – in a dedicated organization – great scientists and great policy analysts, in order to put in the substantial amount of work needed to develop and promote the best possible proposals for improving science policy and infrastructure. It would be a high-risk, potentially very high-return project to attempt. We aren’t aware of any attempts to do something along these lines at the moment, and we think it could be a risk worth taking.

So far, we haven’t been able to find a person or organization who seems both qualified and willing to lead the creation of the sort of organization described in this post. We plan to continue looking for such a person or organization, while continuing to discuss, refine and reflect on these ideas.

If you might be able to get into a position where you’ll have the right expertise in a couple of years, that could be a good option to pursue. Check in with Open Phil to learn more about what they’re looking for.

Read more.

Continue reading →

Are too many people going into biomedical research – or too few?

Are too many people going into biomedical research or too few? As we explore in our new review of the career there are probably too many people entering the field. Biomedical research is a very promising way to make the world a better place if you have a high chance of being a top researcher, but for most people it’s a very tough road and entering could be a costly mistake. In the rest of the post, we’ll explain why and help you figure out whether it might be for you.

Biomedical research is a good path—if you’re a good fit.

We sometimes encounter people who might be a good fit for biomedical research, but who are skeptical about its potential impact. We think this might be misguided because:

  1. There are exciting areas of research that could offer enormous upside, such as anti-aging research, neural implants, gene therapy and synthetic biology.
  2. Potentially very high returns to research with comparatively low costs. According to one estimate, the prevention and treatment of cardiovascular disease in the US in the 1970’s and 1980’s alone had $31 trillion of associated gains. This is on the order of 60 times as large as all spending on medical research over the period. Another analysis estimates that a 1% reduction in cancer mortality in the US would be worth $500 billion (in comparison,

Continue reading →